Similar articles

• Presynaptic neuromuscular transmission block in Guillain-Barré syndrome associated with anti-GQ1b antibodies.

  Wirguin I, Ifergane G, Almog Y, Lieberman D, Bersudsky M, Herishanu YO. Wirguin I, et al. Neuromuscul Disord. 2002 Mar;12(3):292-3. doi: 10.1016/s0960-8966(01)00296-6. Neuromuscul Disord. 2002. PMID: 11801402 No abstract available.
• Guillain-Barré syndrome.

  Kountouras J, Deretzi G, Grigoriadis N, Zavos C, Boziki M, Gavalas E, Katsinelos P, Tzilves D, Giouleme O, Lazaraki G. Kountouras J, et al. Lancet Neurol. 2008 Dec;7(12):1080-1; author reply 1083-5. doi: 10.1016/S1474-4422(08)70247-3. Lancet Neurol. 2008. PMID: 19007730 No abstract available.
• Guillain-Barré syndrome: update on immunobiology and treatment.

  Kaida K, Kusunoki S. Kaida K, et al. Expert Rev Neurother. 2009 Sep;9(9):1307-19. doi: 10.1586/ern.09.77. Expert Rev Neurother. 2009. PMID: 19769446 Review.
• Guillain-Barré syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?

  Jaso R, Sierra M, Calleja J, Valero C, Pascual J. Jaso R, et al. J Neurol. 2010 Mar;257(3):488-9. doi: 10.1007/s00415-009-5400-3. Epub 2009 Nov 22. J Neurol. 2010. PMID: 20229293 No abstract available.
• Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases.

  Yu RK, Usuki S, Ariga T. Yu RK, et al. Infect Immun. 2006 Dec;74(12):6517-27. doi: 10.1128/IAI.00967-06. Epub 2006 Sep 11. Infect Immun. 2006. PMID: 16966405 Free PMC article. Review. No abstract available.